RxDoctor Payments Data

Lindsay Klumpp

Optometrist · Jackson, MINPI 1174923189

Payments from drug & device makers

$3,311in general payments, 2019–2025

Across 136 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$768
  • Amgen$431
  • Alcon$410
  • Novartis$327
  • Bausch & Lomb Americas Inc.$300
  • Sun Pharmaceutical Industries Inc.$255
  • plus $820 from 11 others

What the payments were for

  • Travel & lodging$35411%
  • Food & beverage$2,95789%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,311 in reported general payments places this provider in the 90th percentile of 1,523 optometrist providers in Michigan.

See all optometrist providers in Michigan

Medicare billing

Part B allowed, 2024
$115,032
Medicare patients
569
Services billed
1,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$91,300
LumiganBimatoprost98$58,780
RocklatanNetarsudil Mesylat/Latanoprost69$33,011
Cyclosporine47$22,923
MieboPerfluorohexyloctane/Pf20$17,497
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$12,100
Latanoprost552$11,161
CombiganBrimonidine Tartrate/Timolol26$8,256
Timolol Maleate191$7,487
Travoprost30$6,401
Prednisolone Acetate111$4,969
Brimonidine Tartrate101$4,948
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat177$4,406
SimbrinzaBrinzolamide/Brimonidine Tart13$3,892
Brinzolamide18$2,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$229$158,337195 claims
Aerie Pharmaceuticals, Inc.Rocklatan$53$33,01169 claims
Bausch & Lomb Americas Inc.Miebo$300$17,49720 claims
AlconSimbrinza$410$3,89213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,523 optometrist providers in Michigan.

Other optometrist in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →